Skip to main content
SpringerLink
Log in

Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Contrasting data have been reported so far on the role of reticulated platelets in suboptimal response to antiplatelet therapies. In particular, still unexplored is whether they may contribute to explain the higher risk of thrombotic complications observed in diabetic patients. Aim of the present study was to evaluate the impact of diabetes on the levels of reticulated platelets and its relationship with high residual on-treatment platelet reactivity (HRPR) in patients receiving dual antiplatelet therapy. In patients treated with ASA (100–160 mg) and clopidogrel (75 mg daily) or ticagrelor (90 mg twice a day) platelet reactivity and the reticulated platelets fraction (immature platelets fraction, IPF) were assessed at 30–90 days post-discharge for an acute coronary syndrome or elective PCI. Aggregation was assessed by multiple-electrode aggregometry. We included 386 patients, 158 (40.9 %) diabetics. The percentage of IPF was similar in diabetic and non diabetic patients, both at baseline (3.5 ± 2.5 vs 3.6 ± 2.7 %, p = 0.91) and at 30–90 days re-assessment (3.3 ± 2.1 vs 3.5 ± 2.5 %, p = 0.30), with diabetes not emerging as an independent predictor of IPF above III tertile (adjusted OR [95 %CI] = 0.58 [0.30–1.09], p = 0.10). Diabetic patients displayed an enhanced platelet reactivity and a higher rate of HRPR with ADP antagonists (32.8 vs 22.5 %, p = 0.009). However, no association was found between the percentage of IPF and platelet function (r = −0.004; p = 0.95 for ASPI test, r = −0.04; p = 0.59 for ADP-mediated aggregation), or the rate of HRPR for ADP antagonsist across IPF tertiles. Results were similar for diabetics both receiving clopidogrel and ticagrelor. Diabetic patients display a higher platelet reactivity and suboptimal response to ADP-antagonists. However, the rate of reticulated platelets is neither influenced by diabetic status nor associated with an increased platelet reactivity among diabetic patients receiving dual antiplatelet therapy for a recent acute coronary syndrome or PCI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. De Luca G, Suryapranata H, Marino P (2008) Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status. Prog Cardiovasc Dis 50:352–382

    Article  PubMed  Google Scholar 

  2. Klempfner R, Elis A, Matezky S, Keren G, Roth A, Finkelstein A et al (2015) Temporal trends in management and outcome of diabetic and non-diabetic patients with acute coronary syndrome (ACS): residual risk of long-term mortality persists: insights from the ACS Israeli Survey (ACSIS) 2000–2010. Int J Cardiol 179:546–551

    Article  PubMed  Google Scholar 

  3. De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U et al (2009) Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 207:181–185

    Article  PubMed  Google Scholar 

  4. De Luca G, Małek LA, Maciejewski P, Wasek W, Niewada M, Kamiński B et al (2010) Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the POLISH STEMI registry. Atherosclerosis. 210:516–520

    Article  PubMed  Google Scholar 

  5. Ritsinger V, Saleh N, Lagerqvist B, Norhammar A (2015) High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv. 8:e002328

    Article  PubMed  Google Scholar 

  6. De Luca G, Sauro R, Capasso M, Lanzillo T, Manganelli F, Carbone G, Lanni F, Pagliuca MR, Palmieri V, Serino V, Rosato G, Suryapranata H, Di Lorenzo E (2015) Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction. Diab Vasc Dis Res 12(5):306–314

    Article  PubMed  Google Scholar 

  7. Timmer JR, van der Horst IC, De Luca G, Ottervanger JP, Hoorntje JC, de Boer MJ, Suryapranata H, Dambrink JH, Gosselink M, Zijlstra F, van’t Hof AW, Zwolle Myocardial Infarction Study Group (2005) Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol 95:1375–1377

    Article  PubMed  Google Scholar 

  8. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P et al (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430–2435

    Article  CAS  PubMed  Google Scholar 

  9. Alexopoulos D, Xanthopoulou I, Storey RF, Bliden KP, Tantry US, Angiolillo DJ et al (2014) Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. Am Heart J 168:530–536

    Article  PubMed  Google Scholar 

  10. Ferreiro JL, Angiolillo DJ (2011) Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123:798–813

    Article  PubMed  Google Scholar 

  11. Sharpe PC, Trinick T (1993) Mean platelet volume in diabetes mellitus. Q J Med 86:739–742

    CAS  PubMed  Google Scholar 

  12. Shah B, Sha D, Xie D, Mohler ER 3rd, Berger JS (2012) The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the National Health And Nutrition Examination Survey, 1999-2004. Diabetes Care 35:1074–1078

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CP, Hillman RS (1992) The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 98:637–646

    Article  CAS  PubMed  Google Scholar 

  14. Machin SJ (2013) Development of a consensus standard reference method for immature platelets. Int J Lab Hematol 35:26

    Article  Google Scholar 

  15. Pons I, Monteagudo M, Lucchetti G, Muñoz L, Perea G, Colomina I, Guiu J, Obiols J (2010) Correlation between immature platelet fraction and reticulated platelets. Usefulness in the etiology diagnosis of thrombocytopenia. Eur J Haematol 85(2):158–163

    PubMed  Google Scholar 

  16. Grove EL, Hvas A-M, Kristensen SD (2009) Immature platelets in patients with acute coronary syndromes. Thromb Haemost 101:151–156

    CAS  PubMed  Google Scholar 

  17. Ibrahim H, Nadipalli S, Delao T, Paranilam J, Barker C, Kleiman N (2013) Immature platelets for prediction of clinical events: a possible future target for antiplatelet therapy. Catheter Cardiovasc Interv 81:S108–S109

    Google Scholar 

  18. Verdoia M, Sartori C, Pergolini P, Nardin M, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G (2015) Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes. J Thromb Thrombolysis. doi:10.1007/s11239-015-1279-2

    Google Scholar 

  19. De Luca G, Secco GG, Santagostino M, Venegoni L, Iorio S, Cassetti E, Verdoia M, Coppo L, Di Mario C, Bellomo G, Marino P, Novara Atherosclerosis Study Group (NAS) (2012) Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 22:426–433

    Article  PubMed  Google Scholar 

  20. Verdoia M, Schaffer A, Sartori C, Barbieri L, Cassetti E, Marino P et al (2014) Vitamin D deficiency is independently associated with the extent of coronary artery disease. Eur J Clin Invest 44:634–642

    Article  CAS  PubMed  Google Scholar 

  21. Verdoia M, Pergolini P, Camaro C, Restifo M, Rolla R, Schaffer A et al (2013) PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Blood Coagul Fibrinolysis. 24:411–418

    Article  CAS  PubMed  Google Scholar 

  22. Vidali M, Rolla R, Parrella M, Cassani C, Manzini M, Portalupi MR, Serino R, Prando MD, Bellomo G, Pergolini P (2012) Role of the laboratory in monitoring patients receiving dual antiplatelet therapy. Int J Lab Hematol. 34:484–494

    Article  CAS  PubMed  Google Scholar 

  23. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA, Working Group on High On-Treatment Platelet Reactivity (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919–933

    Article  CAS  PubMed  Google Scholar 

  24. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 1(35):2541–2619

    Google Scholar 

  25. De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW, DESERT Cooperation (2013) Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to bare-metal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention. Am J Cardiol 111:1295–1304

    Article  PubMed  Google Scholar 

  26. De Luca G, Schaffer A, Verdoia M, Suryapranata H (2014) Meta-analysis of 14 trials comparing bypass grafting vs drug-eluting stents in diabetic patients with multivessel coronary artery disease. Nutr Metab Cardiovasc Dis. 24:344–354

    Article  PubMed  Google Scholar 

  27. De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW, DESERT Cooperation (2013) Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation. Diabetes Care 36:1020–1025

    Article  PubMed  PubMed Central  Google Scholar 

  28. De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Carbone G, Pagliuca MR, Rosato G, Di Lorenzo E (2010) Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors and BMS or DES. J Thromb Thrombolysis 30:133–141

    Article  PubMed  Google Scholar 

  29. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM (2007) Diabetes and mortality following acute coronary syndromes. JAMA 298:765–775

    Article  CAS  PubMed  Google Scholar 

  30. De Luca G, Parodi G, Sciagrà R, Bellandi B, Vergara R, Migliorini A, Valenti R, Antoniucci D (2015) Effect of diabetes on scintigraphic infarct size in STEMI patients undergoing primary angioplasty. Diabetes Metab Res Rev 31:322–328

    Article  PubMed  Google Scholar 

  31. Di Giovine G, Verdoia M, Barbieri L, Schaffer A, Aimaretti G, Bellomo G, Marino P, Suryapranata H, Sinigaglia F, De Luca G, Novara Atherosclerosis Study (NAS) Group (2015) Impact of diabetes on fibrinogen levels and its relationship with platelet reactivity and coronary artery disease: a single-centre study. Diabetes Res Clin Pract 109:541–550

    Article  PubMed  Google Scholar 

  32. Verdoia M, Schaffer A, Barbieri L, Aimaretti G, Marino P, Sinigaglia F, Suryapranata H, De Luca G, On behalf of the Novara Atherosclerosis Study Group (NAS) (2015) Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease. Diabetes Metab. doi:10.1016/j.diabet.2015.01.001

    PubMed  Google Scholar 

  33. Verdoia M, Barbieri L, Schaffer A, Cassetti E, Nardin M, Bellomo G, Aimaretti G, Marino P, Sinigaglia F, De Luca G, Novara Atherosclerosis Study Group (NAS) (2014) Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: a single-centre cohort study. Metabolism 63(5):640–646. doi:10.1016/j.metabol.2014.01.010

    Article  CAS  PubMed  Google Scholar 

  34. Droppa M, Tschernow D, Müller KA, Tavlaki E, Karathanos A, Stimpfle F, Schaeffeler E, Schwab M, Tolios A, Siller-Matula JM, Gawaz M, Geisler T (2015) Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). PLoS One 10:e0121620

    Article  PubMed  PubMed Central  Google Scholar 

  35. Migliorini A, Valenti R, Marcucci R et al (2009) High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 120:2214–2221

    Article  CAS  PubMed  Google Scholar 

  36. Breet NJ, Van Werkum JW, Bouman HJ et al (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303:754–762

    Article  CAS  PubMed  Google Scholar 

  37. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505–1516

    Article  CAS  PubMed  Google Scholar 

  38. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F et al (2013) Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 31:3006–3016

    Article  Google Scholar 

  39. Watala C, Boncler M, Pietrucha T, Trojanowski Z (1999) Possible mechanisms of the altered platelet volume distribution in type 2 diabetes: does increased platelet activation contribute to platelet size heterogeneity? Platelets 10:52–60

    Article  CAS  PubMed  Google Scholar 

  40. Khaspekova SG, Ziuriaev IT, Iakushkin VV, IaA Naĭmushin et al (2014) Mean platelet volume: interactions with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels. Biomed Khim. 60:94–108

    Article  CAS  PubMed  Google Scholar 

  41. De Luca G, Verdoia M, Cassetti E, Schaffer A, Di Giovine G, Bertoni A, Di Vito C, Sampietro S, Aimaretti G, Bellomo G, Marino P, Sinigaglia F, Novara Atherosclerosis Study (NAS) Group (2013) Mean platelet volume is not associated with platelet reactivity and the extent of coronary artery disease in diabetic patients. Blood Coagul Fibrinolysis 24:619–624

    Article  PubMed  Google Scholar 

  42. Verdoia M, Schaffer A, Barbieri L, Cassetti E, Nardin M, Bellomo G, Marino P, Sinigaglia F, De Luca G, Novara Atherosclerosis Study (NAS) Group (2014) Diabetes, glucose control and mean platelet volume: a single-centre cohort study. Diabetes Res Clin Pract 104(2):288–294. doi:10.1016/j.diabres.2013.12.020

    Article  PubMed  Google Scholar 

  43. Hoffmann JJ (2014) Reticulated platelets: analytical aspects and clinical utility. Clin Chem Lab Med 52:1107–1117

    Article  CAS  PubMed  Google Scholar 

  44. Guthikonda S, Lev EI, Patel R et al (2007) Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5:490–496

    Article  CAS  PubMed  Google Scholar 

  45. Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, Lev EI (2008) Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 52:743–749

    Article  CAS  PubMed  Google Scholar 

  46. Perl L, Lerman-Shivek H, Rechavia E, Vaduganathan M, Leshem-Lev D, Zemer-Wassercug N, Dadush O, Codner P, Bental T, Battler A, Kornowski R, Lev EI (2014) Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 63:513–517

    Article  CAS  PubMed  Google Scholar 

  47. Vaduganathan M, Zemer-Wassercug N, Rechavia E, Lerman-Shivek H, Perl L, Leshem-Lev D, Orvin K, Kornowski R, Lev EI (2015) Relation between ticagrelor response and levels of circulating reticulated platelets in patients with non-ST elevation acute coronary syndromes. J Thromb Thrombolysis 40:211–217

    Article  CAS  PubMed  Google Scholar 

  48. Ibrahim H, Nadipalli S, DeLao T, Guthikonda S, Kleiman NS (2012) Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness. J Thromb Thrombolysis 33:137–142

    Article  CAS  PubMed  Google Scholar 

  49. Larsen SB, Grove EL, Hvas AM, Kristensen SD (2014) Platelet turnover in stable coronary artery disease—influence of thrombopoietin and low-grade inflammation. PLoS One 9:e85566

    Article  PubMed  PubMed Central  Google Scholar 

  50. Lee EY, Kim SJ, Song YJ, Choi SJ, Song J (2013) Immature platelet fraction in diabetes mellitus and metabolic syndrome. Thromb Res 132:692–695

    Article  CAS  PubMed  Google Scholar 

  51. Mijovic R, Kovacevic N, Zarkov M, Stosic Z, Cabarkapa V, Mitic G (2015) Reticulated platelets and antiplatelet therapy response in diabetic patients. J Thromb Thrombolysis 40:203–210

    Article  CAS  PubMed  Google Scholar 

  52. Eisen A, Lerman-Shivek H, Perl L, Rechavia E, Leshem-Lev D, Zemer-Wassercug N, Dadush O, Kazum S, Codner P, Kornowski R, Lev EI (2015) Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor. J Thromb Thrombolysis 40:70–75

    Article  CAS  PubMed  Google Scholar 

  53. Cesari F, Marcucci R, Gori AM, Caporale R, Fanelli A, Casola G et al (2013) Reticulated platelets predict cardiovascular death in acute coronary syndrome patients: insights from the AMI-florence 2 study. Thromb Haemost 109:846–853

    Article  CAS  PubMed  Google Scholar 

  54. De Luca G, Secco GG, Iorio S, Verdoia M, Bellomo G, Marino P (2012) Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study. Blood Coagul Fibrinolysis 23:756–759

    Article  PubMed  Google Scholar 

  55. Genovese S, De Berardis G, Nicolucci A, Mannucci E, Evangelista V, Totani L et al (2013) Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes. Adv Ther 30:190–202

    Article  CAS  PubMed  Google Scholar 

  56. Paniccia R, Antonucci E, Maggini N, Romano E, Gori AM, Marcucci R et al (2009) Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 131:834–842

    Article  CAS  PubMed  Google Scholar 

  57. Siller-Matula JM, Gruber C, Francesconi M, Dechant C, Jilma B, Delle-Karth G, Grohs K, Podczeck-Schweighofer A, Christ G (2015) The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Sci (Lond). 128(2):121–130

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Azienda Ospedaliera-Universitaria “Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy

    Monica Verdoia, Matteo Nardin, Lucia Barbieri, Alon Schaffer, Paolo Marino & Giuseppe De Luca

  2. Clinical Chemistry, Azienda Ospedaliera-Universitaria “Maggiore della Carità”, Eastern Piedmont University, Novara, Italy

    Patrizia Pergolini, Roberta Rolla & Giorgio Bellomo

  3. Department of Cardiology, UMC St Radboud, Nijmegen, The Netherlands

    Harry Suryapranata

Authors
  1. Monica Verdoia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrizia Pergolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matteo Nardin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberta Rolla
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lucia Barbieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alon Schaffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paolo Marino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giorgio Bellomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Harry Suryapranata
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giuseppe De Luca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe De Luca.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest nor funding source to disclose.

Additional information

On behalf of the Novara Atherosclerosis Study Group (NAS).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Verdoia, M., Pergolini, P., Nardin, M. et al. Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. J Thromb Thrombolysis 42, 245–253 (2016). https://doi.org/10.1007/s11239-016-1348-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-016-1348-1

Keywords

Search

Navigation